SecBot SecBot
SECBOTREPLAY Home › Report › MNKD

MNKD · MannKind announced completion of patient randomization in the U.S

MannKind · PRESS-RELEASE filed Jun 3, 2026 at 06:05 ET

At the news

NEUTRALIMPACT 5/10

PRESS-RELEASE filed Jun 3, 2026 at 06:05 ET

MannKind announced completion of patient randomization in the U.S. Phase 1b INFLO-1 trial and enrollment of the first patient in the global Phase 2 INFLO-2 study for nintedanib DPI (MNKD-201) in idiopathic pulmonary fibrosis. Phase 1b data readout is expected in Q3 2026, representing a key clinical milestone for the program.

  • Phase 1b INFLO-1 patient randomization completed; data readout expected Q3 2026
  • First patient enrolled in global Phase 2 INFLO-2 study (target ~210 participants across ~85 sites)
  • Nintedanib DPI (MNKD-201) uses Technosphere dry powder inhalation technology to deliver drug directly to lungs
  • INFLO-2 is a randomized, double-blind, placebo-controlled trial with 12-week treatment period and 24-week open-label extension

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access